B
BioSpace
AstraZeneca buys into Summit, UniQure drops on 4-year data, FDA on a roll
0:00-20:09
Summit Therapeutics scores a $2 billion equity investment from AstraZeneca to support ivonescimab’s late-stage development; uniQure crashes after four-year data from its Huntington’s disease gene therapy failed to impress; Kyverna Therapeutics brings new light to a struggling CAR T space in autoimmune disease.
Publisher
BioSpace
Published
September 30, 2026
Duration
20 min
Format
Podcast
Category
Issues · Science
Source
RSS feed
B
BioSpace
@biospace
#astrazenecabuys #uniquredrops #yeardata #lifesciences
